CellCentric

CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, a first-in-class oral inhibitor of the p300/CBP transcription co-activation proteins, for relapsed and refractory multiple myeloma.

Inobrodib has been evaluated in over 400 patients and holds FDA Fast Track and orphan drug designations.

Phase 2 dose optimisation data presented at ASH 2025 support progression; a Phase III programme is planned for mid-2026. A $120 million Series C was raised in 2025.